Notices. 60-Day Notice of Information Collection Under Review: National Tracing Center Trace Request and Obliterated Serial Number Trace Request

5,985 words·~27 min read·/register/2006/08/22/06-7103

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 7020-02-P DEPARTMENT OF JUSTICE Bureau of Alcohol, Tobacco, Firearms and Explosives [OMB Number 1140-0043] Agency Information Collection Activities: Proposed Collection; Comments Requested AGENCY: Bureau of Alcohol, Tobacco, Firearms and Explosives, DOJ. ACTION: 60-Day Notice of Information Collection Under Review: National Tracing Center Trace Request and Obliterated Serial Number Trace Request. The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for “sixty days” until October 23, 2006. This process is conducted in accordance with 5 CFR 1320.10. If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Ben Hayes, ATF National Tracing Center, 244 Needy Road, Martinsburg, WV 25401. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. Overview of this information collection:

(1)*Type of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* National Tracing Center Trace Request and Obliterated Serial Number Trace Request.

(3)*Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: ATF F 3312.1 and ATF F 3312.2. Bureau of Alcohol, Tobacco, Firearms and Explosives.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Federal Government. *Other:* State, local, or tribal government. The forms are used by the Federal, State, Local, and International law enforcement community to request that ATF trace firearms used, or suspected to have been used, in crimes.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that 112,123 respondents will complete each form within 6 minutes.

(6)*An estimate of the total public burden (in hours) associated with the collection:* There are an estimated 22,425 annual total burden hours associated with this collection. If additional information is required contact: Lynn Bryant, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, Department of Justice, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: August 17, 2006. Lynn Bryant, Department Clearance Officer, Department of Justice. [FR Doc. E6-13907 Filed 8-21-06; 8:45 am] BILLING CODE 4410-FY-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [OMB Number 1117-0033] Agency Information Collection Activities: Proposed collection; Comments Requested: AGENCY: Drug Enforcement Administration, DOJ. ACTION: 60-Day Notice of Information Collection Under Review: Report of Mail Order Transaction. The Department of Justice (DOJ), Drug Enforcement Administration (DEA), has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for “sixty days” until October 23, 2006. This process is conducted in accordance with 5 CFR 1320.10. If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Mark W. Caverly, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.* , permitting electronic submission of responses. Overview of this information collection:

(1)T *ype of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* Report of Mail Order Transaction.

(3)*Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form Number:* none. Office of Diversion Control, Drug Enforcement Administration, Department of Justice.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Business or other for-profit. *Other:* None. *Abstract:* The Comprehensive Methamphetamine Control Act of 1996 (Pub. L. 104-237)

(MCA)amended the Controlled Substances Act to require that each regulated person who engages in a transaction with a non-regulated person which involves ephedrine, pseudoephedrine, or phenylpropanolamine (including drug products containing these chemicals) and uses or attempts to use the Postal Service or any private or commercial carrier shall, on a monthly basis, submit a report of each such transaction conducted during the previous month to the Attorney General.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that there are twenty-four

(24)total respondents for this information collection. Fourteen

(14)responded on paper at 1 hour for each response and ten

(10)responded at 15 minutes per form, for an annual burden of 168 hours for paper forms and 30 hours for electronic forms.

(6)*An estimate of the total public burden (in hours) associated with the collection:* It is estimated that there are 198 annual burden hours associated with this collection. If additional information is required contact: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: August 17, 2006. Lynn Bryant, Department Clearance Officer, Department of Justice. [FR Doc. E6-13906 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration [OMB Number 1117-0029] Agency Information Collection Activities: Proposed Collection; Comments Requested AGENCY: Drug Enforcement Administration, DOJ. ACTION: 60-Day Notice of Information Collection Under Review: Annual Reporting Requirement for Manufacturers of Listed Chemicals. The Department of Justice (DOJ), Drug Enforcement Administration (DEA), has submitted the following information collection request to the Office of Management and Budget

(OMB)for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for “sixty days” until October 23, 2006. This process is conducted in accordance with 5 CFR 1320.10. If you have comments, especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Mark W. Caverly, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; —Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Enhance the quality, utility, and clarity of the information to be collected; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection:

(1)*Type of Information Collection:* Extension of a currently approved collection.

(2)*Title of the Form/Collection:* Annual Reporting Requirement for Manufacturers of Listed Chemicals.

(3)*Agency form number, if any and the applicable component of the Department sponsoring the collection: Form number:* none. Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice.

(4)*Affected public who will be asked or required to respond, as well as a brief abstract: Primary:* Business or other for-profit. *Other:* None. *Abstract:* This information collection permits the Drug Enforcement Administration to monitor the volume and availability of domestically manufactured listed chemicals. These listed chemicals may be subject to diversion for the illicit production of controlled substances. This information collection is required by law.

(5)*An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* It is estimated that there are one hundred

(100)total respondents for this information collection. One hundred

(100)persons respond annually at 4 hours per response.

(6)*An estimate of the total public burden (in hours) associated with the collection:* It is estimated that there are 400 annual burden hours associated with this collection. If additional information is required contact: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530. Dated: August 17, 2006. Lynn Bryant, Department Clearance Officer, U.S. Department of Justice. [FR Doc. E6-13908 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 8, 2006, Aldrich Chemical Company Inc., DBA Isotec, 3858 Benner Road, Miamisburg, OH 45342-4304, made application by renewal, to the Drug Enforcement Administration

(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II: Drug Schedule Cathinone

(1235)I Methcathinone

(1237)I N-Ethylamphetamine

(1475)I N,N-Dimethylamphetamine

(1480)I Aminorex

(1585)I Gamma hydroxybutyric acid

(2010)I Methaqualone

(2565)I Ibogaine

(7260)I Lysergic acid dethylamide

(7315)I Tetrahydrocannabinols

(7370)I Mescaline

(7381)I 2,5-Dimethoxyamphetamine

(7396)I 3,4-Methylenedioxyamphetamine

(7400)I 3,4-Methylenedioxy-N-ethylamphetamine

(7404)I 3,4-Methylenedioxy-methamphetamine

(7405)I 4-Methoxyamphetamine

(7411)I Psilocybin

(7437)I Psilocyn

(7438)I N-Ethyl-1-phenylcyclohexylamine

(7455)I Dihydromorphine

(9145)I Normorphine

(9313)I Acetylmethadol

(9601)I Alphacetylmethadol Except Levo-Alphacetylmethadol

(9603)I Normethadone

(9635)I Norpipanone

(9636)I 3-Methylfentanyl

(9813)I Amphetamine

(1100)II Methamphetamine

(1105)II Methylphenidate

(1724)Amobarbital

(2125)II Pentobarbital

(2270)II Secobarbital

(2315)II 1-Phenylcyclohexylamine

(7460)II Phencyclidine

(7471)II Phenylacetone

(8501)II 1-Piperidinocyclohexanecarbonitrile

(8603)II Cocaine

(9041)II Codeine

(9050)II Dihydrocodeine

(9120)II Oxycodone

(9143)II Hydromorphone

(9150)II Benzoylecgonine

(9180)II Ethylmorphine

(9190)II Hydrocodone

(9193)II Isomethadone

(9226)II Meperidine

(9230)II Meperidine intermediate-A

(9232)II Merperidine intermediate-B

(9233)II Methadone

(9250)II Methadone intermediate

(9254)II Dextropropoxyphene, bulk, (non-dosage forms)

(9273)II Morphine

(9300)II Normorphine

(9313)II Thebaine

(9333)II Levo-alphacetylmethadol

(9648)II Oxymorphone

(9652)II Fentanyl

(9801)II The company plans to manufacture small quantities of the listed controlled substances to produce isotope labeled standards for drug testing and analysis. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301; and must be filed no later than October 23, 2006. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13849 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 25, 2006, American Radiolabeled Chemicals, Inc., 101 Arc Drive, St. Louis, Missouri 63146, made application by renewal, and by correspondence dated June 2, 2006, to the Drug Enforcement Administration

(DEA)for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Drug Schedule Gamma hydroxybutyric acid

(2010)I Ibogaine

(7260)I Lysergic acid diethylamide

(7315)I Tetrahydrocannabinols

(7370)I Dimethyltryptamine

(7435)I Dihydromorphine

(9145)I Amphetamine

(1100)II Methamphetamine

(1105)II Amobarbital

(2125)II Phencyclidine

(7471)II Phenylacetone

(8501)II Cocaine

(9041)II Codeine

(9050)II Dihydrocodeine(9120) II Oxycodone

(9143)II Hydromorphone

(9150)II Ecgonine

(9180)II Hydrocodone

(9193)II Meperidine

(9230)II Metazocine

(9240)II Morphine

(9300)II Thebaine

(9333)II Oxymorphone

(9652)II Fentanyl

(9801)II The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 23, 2006. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13840 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on March 31, 2006, Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, State College, Pennsylvania 16801, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as an importer of the basic classes of controlled substances listed in Schedule I and II: Drug Schedule Heroin

(9200)I Cocaine

(9041)II Codeine

(9050)II Meperidine

(9230)II Methadone

(9250)II Morphine

(9300)II The company plans to import these controlled substances for the manufacture of reference standards. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 21, 2006. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d),

(e)and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d),

(e)and

(f)are satisfied. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13843 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 6, 2006, Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, NJ 08902, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II: Drug Schedule N-Ethylamphetamine

(1475)I Tetrahydrocannabinols

(7370)I 2,5-Dimethoxyamphetamine

(7396)I 3,4-Methylenedioxyamphetamine

(7400)I 4-Methoxyamphetamine

(7411)I Amphetamine

(1100)II Methamphetamine

(1105)II Methylphenidate

(1724)II Pentobarbital

(2270)II Phenylacetone

(8501)II Hydromorphone

(9150)II Hydrocodone

(9193)II Methadone

(9250)II Methadone Intermediate

(9254)II Morphine

(9300)II Sufentanil

(9740)II Fentanyl

(9801)II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 23, 2006. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13844 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on June 6, 2006, Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, New Jersey 08902, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in Schedule II. The company plans to import the listed controlled substance to manufacture amphetamine. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 21, 2006. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d),

(e)and

(f)are satisfied. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13845 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 15, 2006, Chemic Laboratories, Inc., 480 Neponset Street, Building 7C, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in Schedule II. The company plans to manufacture small quantities of a cocaine derivative for distribution to its customers for the purpose of research. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA **Federal Register** Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA **Federal Register** Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 23, 2006. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13850 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on June 21, 2006, Clinical Trial Services (US), 2661 Audubon Road, Audubon, Pennsylvania 19403, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as an importer of the basic classes of controlled substances listed in Schedule II: Drug Schedule Oxycodone

(9143)II Fentanyl

(9801)II The company plans to import small quantities of the listed controlled substance in dosage form to conduct clinical trials. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 21, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d),

(e)and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d),

(e)and

(f)are satisfied. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13846 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 2, 2005, Noramco Inc., Division of Ortho-McNeil, Inc., 500 Old Swedes Landing Road, Wilmington, Delaware 19801, made application by renewal, and by letter, to the Drug Enforcement Administration

(DEA)for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II: Drug Schedule Morphine-N-Oxide

(9307)I Codeine-N-Oxide

(9053)I Dihydromorphine

(9145)II Amphetamine

(1100)II Methylphenidate

(1724)II Codeine

(9050)II Dihydrocodeine

(9120)II Oxycodone

(9143)II Hydrocodone

(9193)II Morphine

(9300)II Thebaine

(9333)II Oxymorphone

(9652)II The company plans to bulk manufacture the above listed controlled substances for sale and distribution to manufacturers for product development and formulation. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 23, 2006. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13838 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on April 5, 2006, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as an importer of Cocaine (9041), a basic class of controlled substance listed in Schedule II. The company plans to import small quantities of the listed controlled substances for the National Institute of Drug Abuse and other clients. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 21, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d),

(e)and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d),

(e)and

(f)are satisfied. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13839 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 21, 2006, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, P.O. Box 12194, East Institute Drive, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration

(DEA)for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II: Drug Schedule Marihuana

(7360)I Cocaine

(9041)II The Institute will manufacture small quantities of cocaine and marihuana derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by NIDA. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 23, 2006. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13841 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on May 12, 2006, Wildlife Laboratories, Inc., 1401 Duff Drive, Suite 400, Fort Collins, Colorado 80524, made application to the Drug Enforcement Administration

(DEA)by renewal to be registered as an importer of Etorphine Hydrochloride (9059), a basic class of controlled substance listed in Schedule II. The company plans to import the listed controlled substance for sale to its customers. Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 21, 2006. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d),

(e)and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance listed in Schedule I or II are, and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d),

(e)and

(f)are satisfied. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13842 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated April 17, 2006, and published in the **Federal Register** on April 21, 2006, (71 FR 20729), Guilford Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, MD 21224, made application by renewal to the Drug Enforcement Administration

(DEA)to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in Schedule II. The company plans to manufacture a cocaine derivative to be used in clinical research studies. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Guilford Pharmaceuticals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Guilford Pharmaceuticals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: August 15, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6-13848 Filed 8-21-06; 8:45 am] BILLING CODE 4410-09-P DEPARTMENT OF JUSTICE Foreign Claims Settlement Commission Meeting Notice No. 7-06 The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR part 504) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of meetings for the transaction of Commission business and other matters specified, as follows: Date and Time: Thursday, August 31, 2006, at 10 a.m. Subject Matter: Issuance of Proposed Decisions and Amended Final Decisions in claims against Albania. Status: Open. All meetings are held at the Foreign claims Settlement Commission, 600 E Street, NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Administrative Officer, Foreign Claims Settlement Commission, 600 E Street, NW., Room 6002, Washington, DC 20579. Telephone:

(202)616-6988. Dated at Washington, DC. Mauricio J. Tamargo, Chairman. [FR Doc. 06-7103 Filed 8-18-06; 1:36 pm]

Connectionstraces to 8

Traces to 8 documents

CFR

U.S. Code

3 references not yet in our index